New approaches in acute myeloid leukemia.
Today, treatment of patients with acute myeloid leukemia (AML) remains predominantly a "one-fits-all" approach with intensive cytarabine-based chemotherapy as the mainstay, but we are finally beginning to reap the rewards of decades of basic, translational, and clinical research. Developing individualized, "targeted" therapy for each AML patient based on unique molecular features of disease remains a daunting goal, yet one that we can now begin to envision. Hypothesis-based study designs--from preclinical/laboratory experiments to phase 1 and subsequent efficacy trials--provide the foundation for advances in the diagnosis, risk stratification, and treatment of patients with AML. The following is an outline of several key areas of ongoing AML research.
Blum
William
W
Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA. william.blum@osumc.edu
Marcucci
Guido
G
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015195:Drug Design; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D044127:Epigenesis, Genetic / Q000187:drug effects*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D011505:Protein-Tyrosine Kinases